AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19165592 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral therapy (FCBT)
Number of subjects: 35
Study 19165592 — intervention group
Group type: COMPARATOR
Intervention: Child-focused cognitive behavioral therapy (CCBT)
Number of subjects: 35
Study 17890444 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day for 3 days before MDMA challenge (100 mg oral)
Number of subjects: 12
Study 17890444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15042130 — intervention group
Group type: EXPERIMENTAL
Intervention: AX diet (arabinoxylan-rich bread and muffins)
Number of subjects: 15
Study 15042130 — intervention group
Group type: COMPARATOR
Intervention: Control diet (control bread and muffins)
Number of subjects: 15
Study 12968582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 0
Study 10485505 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release etodolac 1200 mg
Number of subjects: 237
Study 10485505 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional etodolac 400 mg
Number of subjects: 237
Study 10485505 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional etodolac 200 mg
Number of subjects: 237
Study 10485505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 7591683 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP with IFN-alpha (2 x 10(6) U, 5 days per week for 12 months)
Number of subjects: 84
Study 7591683 — intervention group
Group type: COMPARATOR
Intervention: VMCP alone
Number of subjects: 84
Study 7591683 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP with IFN-alpha (for stage 3 evaluable patients)
Number of subjects: 84
Study 7591683 — intervention group
Group type: COMPARATOR
Intervention: VMCP alone (for stage 3 evaluable patients)
Number of subjects: 84
Study 7591683 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP/IFN induction arm
Number of subjects: 84
Study 1773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine vaginal suppositories (10 mg) applied for five days
Number of subjects: 224
Study 1773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine (20 mg/day) applied for five days
Number of subjects: 224
Study 1773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine (10 mg/day) applied for three days pre-operatively
Number of subjects: 224
Study 1773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine preparation
Number of subjects: 224
Study 1773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine prophylaxis
Number of subjects: 224
Study 7025500 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(β‐hydroxyethyl)‐rutosides (HR)
Number of subjects: 143
Study 7025500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 30777950 — intervention group
Group type: EXPERIMENTAL
Intervention: heads‐up 3D vision group
Number of subjects: 20
Study 30777950 — intervention group
Group type: COMPARATOR
Intervention: conventional surgery group
Number of subjects: 20
Study 29040125 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal incision technique
Number of subjects: 152
Study 29040125 — intervention group
Group type: COMPARATOR
Intervention: Standard incision technique
Number of subjects: 152
Study 27026043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) + Interferon beta-1a (30 micro g/week)
Number of subjects: 95
Study 27026043 — intervention group
Group type: COMPARATOR
Intervention: Control group (Interferon beta-1a 30 micro g/week)
Number of subjects: 95
Study 25090915 — intervention group
Group type: EXPERIMENTAL
Intervention: General inhibition training
Number of subjects: 0
Study 25090915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue‐Specific inhibition training
Number of subjects: 0
Study 25090915 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol No‐Go training
Number of subjects: 0
Study 25090915 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25090915 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study 23078200 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland mobilisations plus range‐of‐motion exercises
Number of subjects: 90
Study 23078200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs plus self‐SNAG exercises
Number of subjects: 90
Study 23078200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19820906 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in combination with simultaneous chemotherapy
Number of subjects: 0
Study 19820906 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation and perioperative chemotherapy
Number of subjects: 0
Study 17255855 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 4 mL/kg (T26R) and PEEP lowered by 2 cm H2O every 4 mins.
Number of subjects: 18
Study 17255855 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 6 mL/kg (T(end)).
Number of subjects: 18
Study 15201815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training with bench model simulators (silicone tubing or live rat vas deferens)
Number of subjects: 50
Study 15201815 — intervention group
Group type: COMPARATOR
Intervention: Didactic training alone
Number of subjects: 50
Study 11914251 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA 2.5 mg
Number of subjects: 3
Study 11914251 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA 5.0 mg
Number of subjects: 3
Study 11914251 — intervention group
Group type: COMPARATOR
Intervention: CEE (0.625 mg)
Number of subjects: 3
Study 11914251 — intervention group
Group type: COMPARATOR
Intervention: CEE alone
Number of subjects: 3
Study 9210501 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME (cyclosporine for microemulsion)
Number of subjects: 0
Study 9210501 — intervention group
Group type: COMPARATOR
Intervention: CsA (original formulation)
Number of subjects: 0
Study 8217065 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 400
Study 8217065 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 400
Study 8217065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 3621278 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (two with class IC and two with class IA action)
Number of subjects: 502
Study 3621278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 31958932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattoo group (endoscopic tattooing with carbon nanoparticles)
Number of subjects: 120
Study 31958932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattoo-inoperable patients (chemoradiotherapy after tattooing)
Number of subjects: 120
Study 31958932 — intervention group
Group type: COMPARATOR
Intervention: Non-tattoo-inoperable patients (chemoradiotherapy without tattooing)
Number of subjects: 120
Study 31055046 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 20 mg
Number of subjects: 40
Study 31055046 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 40 mg
Number of subjects: 40
Study 31055046 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 80 mg
Number of subjects: 40
Study 31055046 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 120 mg
Number of subjects: 40
Study 31055046 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS (all doses)
Number of subjects: 40
Study 27140680 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (UNI)
Number of subjects: 22
Study 27140680 — intervention group
Group type: COMPARATOR
Intervention: Bilateral resistance training (BIL)
Number of subjects: 22
Study 26396164 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-training programme (three times/week over 12 weeks)
Number of subjects: 96
Study 26396164 — intervention group
Group type: COMPARATOR
Intervention: Training + physical activity
Number of subjects: 96
Study 26396164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 24368613 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 65
Study 24368613 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 65
Study 24368613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MBIR
Number of subjects: 65
Study 24368613 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose FBP
Number of subjects: 65
Study 23070400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg/day
Number of subjects: 30
Study 23070400 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 30
Study 19244369 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) diet
Number of subjects: 11
Study 19244369 — intervention group
Group type: COMPARATOR
Intervention: AA diet
Number of subjects: 11
Study 19244369 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP diet
Number of subjects: 11
Study 17634486 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4440
Study 15354390 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 12
Study 15354390 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/rTMS
Number of subjects: 12
Study 15354390 — intervention group
Group type: COMPARATOR
Intervention: placebo/rTMS
Number of subjects: 12
Study 15354390 — intervention group
Group type: COMPARATOR
Intervention: levodopa/sham stimulation
Number of subjects: 12
Study 11436671 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐Viva‐2 circuit
Number of subjects: 16
Study 11436671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson‐B circuit
Number of subjects: 16
Study 11436671 — intervention group
Group type: COMPARATOR
Intervention: Manual hyperinflation technique
Number of subjects: 16
Study 10095804 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate administration (0.25 mg day‐1) plus 60 mg day‐1 of Fe2+
Number of subjects: 30
Study 10095804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (60 mg day‐1 of Fe2+)
Number of subjects: 30
Study 7831065 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 60 mg
Number of subjects: 20
Study 7831065 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 120 mg
Number of subjects: 20
Study 7831065 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 20
Study 3354874 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg IV
Number of subjects: 8
Study 3354874 — intervention group
Group type: COMPARATOR
Intervention: Physostigmine 2.0 mg IV
Number of subjects: 8
Study 1298332 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Bradykinin (8 mg/mL)
Number of subjects: 10
Study 1298332 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 10
Study 568923 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit sexual stimuli
Number of subjects: 45
Study 568923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexplicit sexual stimuli
Number of subjects: 45
Study 568923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 31666084 — intervention group
Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol 62.5/25 μg once-daily
Number of subjects: 0
Study 31666084 — intervention group
Group type: COMPARATOR
Intervention: umeclidinium 62.5 μg once-daily
Number of subjects: 0
Study 31666084 — intervention group
Group type: COMPARATOR
Intervention: salmeterol 50 μg twice-daily
Number of subjects: 0
Study 31666084 — intervention group
Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol
Number of subjects: 0
Study 27893938 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVESTRONG at the YMCA exercise program
Number of subjects: 186
Study 27893938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 25896890 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate >26 mmol/L
Number of subjects: 3586
Study 25896890 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate <22 mmol/L
Number of subjects: 3586
Study 25896890 — intervention group
Group type: COMPARATOR
Intervention: Serum bicarbonate 22 to 26 mmol/L
Number of subjects: 3586
Study 23603648 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat lateral decubitus position
Number of subjects: 50
Study 23603648 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-degree tilt lateral decubitus position
Number of subjects: 50
Study 23603648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 50
Study 21314449 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes a day of walking 5 days a week in one continuous long bout (LB)
Number of subjects: 60
Study 21314449 — intervention group
Group type: EXPERIMENTAL
Intervention: three short 10-minute bouts (SB) of walking a day
Number of subjects: 60
Study 21314449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 19843669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1C diet (single dose of cruciferous vegetables)
Number of subjects: 73
Study 19843669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2C diet (double dose of cruciferous vegetables)
Number of subjects: 73
Study 19843669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1C+A diet (single dose of cruciferous and apiaceous vegetables)
Number of subjects: 73
Study 19843669 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 73
Study 19843669 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 activity recovery after removal of apiaceous vegetables
Number of subjects: 73
Study 16915511 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofile, heavy-weight, rigid mesh (group A)
Number of subjects: 90
Study 16915511 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth, heavy-weight variant of polypropylene (group B)
Number of subjects: 90
Study 16915511 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin/polypropylene compound mesh (group C)
Number of subjects: 90
Study 14755652 — intervention group
Group type: EXPERIMENTAL
Intervention: Biexponential signal decay observed in the cortex of the intact mouse brain; ADC drop in both components during global ischemia; shift from rapidly diffusing component to slowly diffusing component during global ischemia.
Number of subjects: 0
Study 14755652 — intervention group
Group type: EXPERIMENTAL
Intervention: Biexponential function applied to erythrocyte samples.
Number of subjects: 0
Study 11734734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal trivalent influenza vaccine (CAIV) - 3 lots (A/Shenzhen/227/95 (H1N1), A/Wuhan/359/95 (H3N2), B/Harbin/7/94-like)
Number of subjects: 474
Study 11734734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 5)
Number of subjects: 474
Study 9203102 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA barrier (n = 16)
Number of subjects: 30
Study 9203102 — intervention group
Group type: COMPARATOR
Intervention: ePTFE barrier (n = 14)
Number of subjects: 30
Study 8477303 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 0
Study 8477303 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study 3320595 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of GHQ information
Number of subjects: 0
Study 3320595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback of GHQ information)
Number of subjects: 0
Study 31537563 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health check from the general practitioner (GP)
Number of subjects: 1104
Study 31537563 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1104
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative health consequences‐graphic ad
Number of subjects: 7812
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social consequences‐intended emotive ad
Number of subjects: 7812
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefits of quitting‐informational ad
Number of subjects: 7812
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefits of quitting‐graphic ad
Number of subjects: 7812
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking ads viewed alone
Number of subjects: 7812
Study 28441097 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic ads viewed in competitive contexts
Number of subjects: 7812
Study 25394242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 405
Study 25394242 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 405
Study 25394242 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on admission
Number of subjects: 405
Study 25394242 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients by day 7
Number of subjects: 405
Study 25394242 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated soluble RAGE on admission
Number of subjects: 405
Study 25394242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression analysis
Number of subjects: 405
Study 23276397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisms‐Active
Number of subjects: 54
Study 23276397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisms‐Imagery
Number of subjects: 54
Study 21529247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) with bovine bone mineral (BBM)
Number of subjects: 26
Study 21529247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM)
Number of subjects: 26
Study 21529247 — intervention group
Group type: COMPARATOR
Intervention: Control group: 70% BBM and 30% autogenous bone (AB)
Number of subjects: 26
Study 18485164 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate repair
Number of subjects: 165
Study 18485164 — intervention group
Group type: COMPARATOR
Intervention: Delayed repair (8‐ to 12‐hour delay)
Number of subjects: 165
Study 16551139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered behavioral family intervention
Number of subjects: 126
Study 16551139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered behavioral family intervention plus brief therapist telephone assistance
Number of subjects: 126
Study 12105157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, heparin, and meloxicam
Number of subjects: 120
Study 10202220 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (50/250 microg bid) via a single Diskus inhaler (combination)
Number of subjects: 371
Study 10202220 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid via one Diskus inhaler and fluticasone propionate 250 microg bid via another (concurrent)
Number of subjects: 371
Study 10202220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 371
Study 7753538 — intervention group
Group type: EXPERIMENTAL
Intervention: Venting drilling with intramedullary plug
Number of subjects: 0
Study 7753538 — intervention group
Group type: COMPARATOR
Intervention: Standard cemented hip replacement without venting
Number of subjects: 0
Study 2407660 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Ne laser
Number of subjects: 100
Study 2407660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100
Study 2407660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7008938 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading course of ICRF-159
Number of subjects: 82
Study 7008938 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen of ICRF-159
Number of subjects: 82
Study 31400240 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention (TBI)
Number of subjects: 780
Study 31400240 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided brief intervention (CBI)
Number of subjects: 780
Study 31400240 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 780
Study 31914437 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg intravitreal injections every 4 weeks, adjusted based on CSMT changes
Number of subjects: 48
Study 30422777 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Responsible Beverage Service training (WayToServe - WTS)
Number of subjects: 309
Study 30422777 — intervention group
Group type: COMPARATOR
Intervention: Usual and Customary live Responsible Beverage Service training (UC)
Number of subjects: 309
Study 27471208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 1247
Study 27471208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 23942152 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal/BLS instructor (RBI) group
Number of subjects: 175
Study 23942152 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal/non‐BLS instructor (RNI) group
Number of subjects: 175
Study 23942152 — intervention group
Group type: COMPARATOR
Intervention: Traditional/BLS instructor (TBI) group
Number of subjects: 175
Study 23942152 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (RBI and RNI)
Number of subjects: 175
Study 23294776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (dula, LY2189265) - a once-weekly glucagon-like peptide-1 analog
Number of subjects: 0
Study 23294776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive scheme (stage 1)
Number of subjects: 0
Study 23294776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed scheme (stage 2)
Number of subjects: 0
Study 20175947 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (5-10 minute warm-up, 15 minute walking, 5-10 minute cool-down, three times per week)
Number of subjects: 60
Study 20175947 — intervention group
Group type: COMPARATOR
Intervention: No exercise program (control group)
Number of subjects: 60
Study 17278015 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 376